Physician profile
Dorothy Buckner
NPI 1275681355
$4,606.59
in general payments reported to CMS, 2019-2025
24 companies · $883 in 2025
The $883 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $237 · 2021: $299 · 2022: $1,130 · 2023: $494 · 2024: $339 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.62 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $680.02 | 2020-2025 | |
| Pfizer INC. | $506.39 | 2019-2022 | |
| Janssen Biotech, INC. | $469.22 | 2020-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $400.78 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $350.30 | 2019-2025 | |
| Leo Pharma INC. | $268.53 | 2021-2023 | Adbry |
| Celgene Corporation | $266.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $241.69 | 2020-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $233.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $219.93 | 2022-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $193.99 | 2024-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $158.25 | 2022 | |
| Dermira, INC. | $135.14 | 2019 | |
| Abbvie INC. | $118.01 | 2024 | |
| Amgen INC. | $94.60 | 2019-2025 | Otezla, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $85.23 | 2022 | |
| Dermavant Sciences, INC. | $38.97 | 2024 | Vtama |
| Epi Health, LLC | $31.45 | 2019 | |
| Biofrontera INC. | $29.07 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $27.43 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $17.73 | 2021 | |
| Medline Industries LP | $14.85 | 2019 | |
| Lilly USA, LLC | $12.92 | 2019 | |
| Almirall LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothy Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.